-
2024-510947-71-00
5
2022-11-21
Chronic Myeloid Leukemia
-
2023-508869-32-00
5
2022-11-10
Cancer - Plasma cell myeloma recurrent
-
2023-505628-67-00
5
2022-10-28
Relapsed and Refractory Follicular Lymphoma
-
2023-505579-53-00
5
2022-10-25
Diffuse large B-cell lymphoma (DLBCL)
-
2023-509408-13-00
6
2022-09-20
Solid tumors
-
2023-505639-11-00
5
2022-09-14
Spinal Muscular Atrophy
-
2023-509657-31-00
5
2022-08-24
Paroxysmal nocturnal haemoglobinuria (PNH)
-
2023-507933-12-00
5
2022-08-18
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
-
2023-504737-41-00
5
2022-06-10
Moderately to Severely Active Crohn's Disease
-
2023-507795-51-00
5
2022-05-17
atherosclerotic heart and blood vessel disease (the narrowing of arter
-
2023-508897-27-00
5
2022-04-28
Multiple Myeloma
-
2023-506359-68-00
5
2022-04-08
Active Proliferative Lupus Nephritis
-
2023-503640-14-00
5
2022-02-17
Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
-
2023-504884-17-00
5
2022-02-04
Proteinuria
-
2024-511492-15-00
5
2021-12-09
Duchenne Muscular Dystrophy
-
2023-507974-42-00
4
2021-12-01
Moderate to Severe Ulcerative Colitis
-
2022-501067-40-00
5
2021-11-30
Moderately to Severely Active Ulcerative Colitis
-
2024-510735-21-00
5
2021-11-26
Atherosclerotic cardiovascular disease (ASCVD)
-
2023-508723-12-00
5
2021-09-27
gastroenteropancreatic neuroendocrine tumors
-
2024-512038-13-00
5
2021-09-16
Metastatic or unresectable locally advanced BRAF V600E/K mutation posi
-
2023-508308-40-00
5
2021-07-30
Metastatic (stage IV) squamous or nonsquamous non-small cell lung canc
-
2022-502100-70-00
10
2021-06-23
Participants with Microsatellite Instability-High (MSI-H) or Mismatch
-
2023-504684-16-00
5
2021-06-05
follicular lymphoma (FL) and marginal zone lymphoma (MZL)
-
2023-503995-26-00
5
2021-05-11
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer